Stroma-Directed Molecular Targeted Therapy in Gastric Cancer
AbstractRecent studies in molecular and cellular biology have shown that tumor growth and metastasis are not determined by cancer cells alone, but also by a variety of stromal cells. Tumor stroma contains abundant extracellular matrix and several types of cells, including carcinoma-associated fibroblasts (CAFs), endothelial cells, pericytes and inflammatory cells including macrophages. In gastric cancer tissues, tumor cells express platelet-derived growth factor (PDGF)-B. Stromal cells, including CAFs, pericytes and lymphatic endothelial cells, express PDGF receptor (PDGFR)-β. Administration of PDGFR tyrosine kinase inhibitor significantly decreases stromal reaction, lymphatic vessel area and pericyte coverage of tumor microvessels. Administration of PDGFR tyrosine kinase inhibitor in combination with cytotoxic chemotherapeutic drug(s) impairs the progressive growth and metastasis of gastric cancer. Activated stroma might serve as a novel therapeutic target in cases of gastric cancer. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Kitadai, Y.; Kodama, M.; Shinagawa, K. Stroma-Directed Molecular Targeted Therapy in Gastric Cancer. Cancers 2011, 3, 4245-4257.
Kitadai Y, Kodama M, Shinagawa K. Stroma-Directed Molecular Targeted Therapy in Gastric Cancer. Cancers. 2011; 3(4):4245-4257.Chicago/Turabian Style
Kitadai, Yasuhiko; Kodama, Michiyo; Shinagawa, Kei. 2011. "Stroma-Directed Molecular Targeted Therapy in Gastric Cancer." Cancers 3, no. 4: 4245-4257.